Verastem, Inc. (VSTM) Form 8-K — Oct 14, 2026
$VSTMForm 8-KItems 2.02, 5.02, 7.01, 8.01, 9.01Filed Oct 14, 2026, 6:08 AM ET0001104659-26-115687Original filing
Verastem announced that Daniel Paterson will retire as President and CEO effective January 1, 2027, with board member Michael Bailey — former CEO of AVEO Pharmaceuticals — appointed as successor. Paterson will remain on the board and as an advisor, and Bailey's compensation terms will be disclosed in an amended 8-K. The company furnished preliminary Q3 2026 results: net product revenue of $23.9-24.1 million, roughly double the $11.2 million reported a year ago, with cash and investments of $172.8 million at quarter-end versus $137.7 million a year prior.
Key figures
- Revenue
- $23.9-24.1 million (Q3 2026 net product revenue, preliminary)
- Guidance
- Phase 3 first-line mPDAC trial of VS-7375 expected to open by year-end 2026; Blister Pack NDA priority review for Q1 2027
- Revenue Yoy
- vs $11.2 million in Q3 2025 (roughly doubled)
- Cash Position
- $172.8 million as of September 30, 2026
- Pdac 2 Lplus ORR
- 41% (9/22)
- Pdac DCR 2 Lplus
- 86%
- Prior year cash
- $137.7 million as of September 30, 2025
- Pdac 2 L ORR 900mg
- 50% (4/8)
- Nsclc 1 L ORR triplet
- 75% (6/8)
- M CRC 3 Lplus ORR 900mg
- 33% (2/6)
- Nsclc 2 Lplus ORR 600mg
- 43% (10/23)
- AE discontinuation rate 900mg
- 2%
- Six month OS rate pdac 2 Lplus
- 80%
- Six month PFS rate pdac 2 Lplus
- 67%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.